Go Pro
NYSE:NVO

Novo Nordisk A/S Q2 2026 Earnings Report

Novo Nordisk A/S logo
$44.16 -2.93 (-6.22%)
Closing price 08/4/2026 03:59 PM Eastern
Extended Trading
$44.82 +0.66 (+1.50%)
As of 09:25 AM Eastern
Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Massive. Learn more.

Novo Nordisk A/S EPS Results

Actual EPS
$0.94
Consensus EPS
N/A
Beat/Miss
N/A
One Year Ago EPS
N/A

Novo Nordisk A/S Revenue Results

Actual Revenue
$11.98 billion
Expected Revenue
N/A
Beat/Miss
N/A
YoY Revenue Growth
N/A

Novo Nordisk A/S Announcement Details

Quarter
Q2 2026
Time
After Market Closes
Conference Call Date
N/A
Conference Call Time
N/A

Upcoming Earnings

Novo Nordisk A/S' Q3 2026 earnings is estimated for Wednesday, August 5, 2026, based on past reporting schedules

Conference Call Resources

Novo Nordisk A/S Earnings Headlines

ALERT: Drop these 5 stocks before the market opens tomorrow!
The Wall Street Journal is already raising the alarm about a potential market crash, and Weiss Ratings research points to the first half of 2026 as a particularly rough stretch for certain holdings. Some of America's most popular stocks could take serious damage as a radical market shift plays out. Analysts at Weiss Ratings have identified five names you may want to remove from your portfolio before this unfolds. If any of these are in your portfolio, now is the time to review your positions.tc pixel
See More Novo Nordisk A/S Headlines
Get Earnings Announcements in your inbox

Want to stay updated on the latest earnings announcements and upcoming reports for companies like Novo Nordisk A/S? Sign up for Earnings360's daily newsletter to receive timely earnings updates on Novo Nordisk A/S and other key companies, straight to your email.

About Novo Nordisk A/S

Novo Nordisk A/S (NYSE:NVO) is a Danish multinational pharmaceutical company headquartered in Bagsværd, Denmark, best known for its leadership in diabetes care and metabolic health. The company traces its roots to early Danish insulin production in the 1920s and was established in its current form through a 1989 merger of predecessor companies. Novo Nordisk develops, manufactures and markets pharmaceutical products and devices that address chronic and serious diseases, with a strong emphasis on long-term treatment and patient support.

The company’s core product portfolio centers on diabetes therapies, including a range of insulins and modern incretin-based treatments. Novo Nordisk has been a major commercial and scientific driver of GLP-1 receptor agonists, marketed under well-known brand names for glucose control and weight management. In addition to diabetes and obesity medicines, the company supplies treatments for haemophilia and other rare bleeding disorders, as well as growth disorders and hormone replacement therapies. Its offerings combine pharmaceuticals with delivery devices and patient services aimed at improving adherence and outcomes.

Research and development are central to Novo Nordisk’s strategy, with continued investment in next-generation medicines for metabolic, cardiovascular and rare diseases. The company operates global manufacturing and distribution networks and markets its products broadly, with significant commercial operations in the United States, Europe and other international markets. Novo Nordisk also engages in partnerships and licensing arrangements with academic institutions, biotechnology firms and healthcare organizations to support innovation and expand access to therapies.

Leadership is focused on long-term innovation and patient-centric care; the company is led by President and CEO Lars Fruergaard Jørgensen. Novo Nordisk positions itself as a specialist pharmaceutical company with a mission to improve the lives of people with chronic conditions through medical innovation, comprehensive treatment solutions and support services for patients and healthcare providers.

View Novo Nordisk A/S Profile